CDK 4/6 Inhibitor Ribociclib in Combination With Docetaxel Plus Prednisone in mCRPC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase Ib/II study of the CDK 4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer
Clin. Cancer Res 2022 Feb 17;[EPub Ahead of Print], I de Kouchkovsky, A Rao, BA Carneiro, L Zhang, C Lewis, A Phone, EJ Small, T Friedlander, L Fong, PL Paris, CJ Ryan, RZ Szmulewitz, R AggarwalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.